7-ketocholesterol-induced Inflammation: Involvement of Multiple Kinase Signaling Pathways Via NFκB but Independently of Reactive Oxygen Species Formation
Overview
Affiliations
Purpose: 7-Ketocholesterol (7KCh) accumulates in oxidized lipoprotein deposits and is known to be involved in macrophage foam cell formation and atherosclerosis. 7-KCh is present in the primate retina and is associated with oxidized lipoprotein deposits located in the choriocapillaris, Bruch's membrane, and retinal pigment epithelium (RPE). 7-KCh can also be formed in the retina as a consequence of light-induced iron release. The purpose of this study was to examine the signaling pathways involved in the 7KCh-mediated inflammatory response focusing on three cytokines, VEGF, IL-6, and IL-8.
Methods: ARPE-19 cells were treated with 7KCh solubilized in hydroxypropyl-β-cyclodextrin. Cytokines were quantified by qRT-PCR (mRNA) and ELISA (protein) using commercially available products. NFκB activation was determined by IκBα mRNA induction.
Results: Treatment of ARPE-19 cells with 15 μM 7KCh markedly induced the expression of VEGF, IL-6, and IL-8. No increase in NOX-4 expression or ROS formation was detected. 7KCh induced the phosphorylation of ERK1/2 and p38MAPK, and inhibitors to these kinases markedly reduced the cytokine expression but did not affect the IκBα mRNA expression. By contrast, inhibition of PI3K and PKCζ significantly decreased the cytokine and IκBα mRNA expression. Inhibition of the IκB kinase complex essentially ablated all cytokine induction.
Conclusions: 7KCh induces cytokines via three kinase signaling pathways, AKT-PKCζ-NFκB, p38 MAPK, and ERK. The MAPK/ERK pathways seem to preferentially enhance cytokine induction downstream from NFκB activation. The results of this study suggest that 7KCh activates these pathways through interactions in the plasma membrane, but the mechanism(s) remains unknown.
Phytol from prevents NF-κB-mediated inflammatory responses during macrophage polarization.
Duraisamy P, Angusamy A, Ravi S, Krishnan M, Martin L, Manikandan B 3 Biotech. 2024; 14(3):80.
PMID: 38375513 PMC: 10874368. DOI: 10.1007/s13205-024-03924-9.
Yu Y, Liu Y, Meng Z Front Pharmacol. 2024; 15:1356324.
PMID: 38333011 PMC: 10850396. DOI: 10.3389/fphar.2024.1356324.
Pariente A, Pelaez R, Ochoa R, Perez-Sala A, Villanueva-Martinez A, Bobadilla M Pharmaceutics. 2023; 15(11).
PMID: 38004569 PMC: 10675123. DOI: 10.3390/pharmaceutics15112590.
Pariente A, Perez-Sala A, Ochoa R, Bobadilla M, Villanueva-Martinez A, Pelaez R Int J Mol Sci. 2023; 24(8).
PMID: 37108627 PMC: 10144535. DOI: 10.3390/ijms24087459.
Leow D, Cheah I, Fong Z, Halliwell B, Ong W Int J Mol Sci. 2023; 24(6).
PMID: 36982572 PMC: 10056831. DOI: 10.3390/ijms24065498.